Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05400317
PHASE3
A Study to Evaluate the Efficacy and Safety of AD-218
Sponsor: Addpharma Inc.
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-218
Official title: A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
520
Start Date
2022-07-27
Completion Date
2026-06-30
Last Updated
2025-02-05
Healthy Volunteers
No
Conditions
Interventions
DRUG
AD-218
PO, Once daily(QD), 12weeks
DRUG
AD-218A
PO, Once daily(QD), 12weeks
Locations (1)
Yeongnam University Hospital
Daegu, Nam-gu, South Korea